882679-40-5

Usage

Uses

Used in Pharmaceutical Development:
METHYL 4-METHYL-3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)BENZOATE is used as a building block for the development of pharmaceuticals. Its unique structure and properties make it a valuable tool for researchers in medicinal chemistry, aiding in the creation of new drugs and therapeutic agents.
Used in Agrochemical Development:
In the agrochemical industry, METHYL 4-METHYL-3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)BENZOATE is utilized as a building block for the development of agrochemicals. Its versatility and compatibility with various reaction conditions make it a useful compound in the creation of new agricultural chemicals.
Used in Organic Synthesis:
METHYL 4-METHYL-3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)BENZOATE is used as a reagent in organic synthesis, particularly for acylation and alkylation reactions. Its stability and compatibility with a variety of solvents and reaction conditions make it a versatile and useful compound in various chemical applications.

Upstream product

• 1350764-46-3 CF₃C₆H₄SO₂O(C₆H₃(CH₃)COOCH₃) 
• 25015-63-8 4,4,5,5-tetramethyl-[1,3,2]-dioxaboralane 
• 104901-43-1 methyl 3-bromo-4-methylbenzoate 
• 73183-34-3 bis(pinacol)diborane 
• 90347-66-3 methyl 3-iodo-4-methylbenzoate 
• 82998-57-0 3-iodo-4-toluic acid 
• 876189-18-3 [5-(methoxycarbonyl)-2-methylphenyl]boronic acid 
• 76-09-5 2,3-dimethyl-2,3-butane diol 
• 99-75-2 4-methyl-benzoic acid methyl ester 
• 170230-88-3 3-carboxy-6-methylphenylboronic acid 
• 7697-26-9 3-bromo-4-methylbenzoic acid 

Downstream Products

• 1221343-14-1 1-(hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)carboxylic acid 
• 1393479-22-5 methyl 4-methyl-3-(2,2,2-trifluoroethyl)benzoate 
• 1459216-73-9 (R)-methyl 3-(5-amino-6-(1-(4-chlorophenyl)ethylamino)pyrazin-2-yl)-4-methylbenzoate 
• 1533442-82-8 methyl 4-methyl-3-(1H-pyrazol-5-yl)benzoate 

Relevant academic research and scientific papers

Catalytic Synthesis of Atropisomeric o-Terphenyls with 1,2-Diaxes via Axial-to-Axial Diastereoinduction

Herein, we report a modular and convergent strategy for the assembly of atropisomeric o-terphenyls with 1,2-diaxes via palladium/chiral norbornene cooperative catalysis and axial-to-axial diastereoinduction. Readily available aryl iodides, 2,6-substituted aryl bromides, and potassium aryl trifluoroborates are used as the building blocks, laying the foundation for diversity-oriented synthesis of these scaffolds (46 examples). Other features include the unique axial-to-axial diastereoinduction mode, construction of two axes in a single operation, and step economy. DFT calculations are performed to rationalize the axial-to-axial diastereoinduction process. Synthetic utilities of this method in preparation of atropisomeric oligophenyls, chiral catalysts, and ligands are demonstrated.

1, 1 '-biphenyl-2, 6-diphenol compound and application thereof

The invention discloses a 1, 1 '-biphenyl-2, 6-diphenol compound and application thereof, and the 1, 1'-biphenyl-2, 6-diphenol compound is a new compound and has good biological activity. Through an in-vitro tumor cell activity experiment method, it is fo

Design and Discovery of N-(2-Methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers

RAS oncogenes have been implicated in >30% of human cancers, all representing high unmet medical need. The exquisite dependency on CRAF kinase in KRAS mutant tumors has been established in genetically engineered mouse models and human tumor cells. To date

C-H borylation by platinum catalysis

Herein, we describe the platinum-catalyzed borylation of aromatic C-H bonds. N-Heterocyclic carbene-ligated platinum catalysts are found to be efficient catalysts for the borylation of aromatic C(sp2)-H bonds when bis(pinacolato)diboron is used as the boron source. The most remarkable feature of these Pt catalysts is their lack of sensitivity towards the degree of steric hindrance around the C-H bonds undergoing the borylation reaction. These Pt catalysts allow for the synthesis of sterically congested 2,6-disubstituted phenylboronic esters, which are otherwise difficult to synthesize using existing C-H borylation methods. Furthermore, platinum catalysis allows for the site-selective borylation of the C-H bonds ortho to fluorine substituents in fluoroarene systems. Preliminary mechanistic studies and work towards the synthetic application of this platinum catalyzed C-H borylation process are described.

TRICYCLIC COMPOUND AND USE THEREOF

The present invention relates to: a compound selected from the group consisting of a tricyclic compound having the structure of formula I, a pharmaceutically acceptable salt, an isomer, a solvate and a precursor thereof; and a use thereof. The compound effectively controls GPR40, and thus, can be effectively used for the prophylaxis or treatment of diseases associated with GPR40, for example, diabetes and many other diseases.

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF

Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds and combinations of such compounds and other therapeutic agents.

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS

Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds.

BORON-CONTAINING DIACYLHYDRAZINES

The present disclosure provides boron-containing diacylhydrazines having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, and R5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.

A benzoboroxole-functionalized monolithic column for the selective enrichment and separation of cis-diol containing biomolecules

A benzoboroxole-functionalized monolithic column was synthesized, which exhibited the best specificity and affinity towards cis-diol containing biomolecules as compared with the boronate affinity monolithic columns reported as well as significant secondar

Palladium-catalyzed borylation of aryl arenesulfonates with dialkoxyboranes

The cross-coupling of aryl arenesulfonates with dialkoxyboranes proceeded in the presence of Bu4NI and a catalytic amount of [Pd(dba) 2]/1,1'-bis(di-tert-butylphosphano)ferrocene, giving good yields of the corresponding arylboronates. The protocols tolerate a wide range of functional groups, including ester, nitrile, and ketone.